| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Cisplatin (CDDP; cis-Diaminodichloroplatinum; Trade names: Platinol; PlatinolAQ among others), an inorganic platinum complex acting as a DNA intercalating agent, is a widely used and classic chemotherapeutic drug and a potent inducer of growth arrest and apoptosis in a variety of cell types. It has been widely used to treat a wide range of cancers, including testicular, ovarian, cervical, breast, bladder, head and neck, esophageal, lung, mesothelioma, brain tumors, and neuroblastoma. It has also been used as a monotherapy or as a component in combination therapy. When administered intravenously (IV), cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups in DNA, such as GC-rich sites, creating cross-links between DNA strands as well as intrastrand and interstrand. This stops DNA synthesis, which stops cell growth and causes apoptosis.
| Targets |
DNA Alkylator/Crosslinker
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
L1210/0 cells are kept in an exponential suspension culture in McCoy's medium 5a (modified), supplemented with 15% calfserum and Fungizone, at 37 °C in a humidified atmosphere of 5% CO2. For two hours at 37°C, L1210/0 cells are incubated in 7 μg/mL of cisplatin. The cells are centrifuged, once again cleaned, resuspended in fresh medium at 30 × 103 to 50 × 103 cells/mL, and incubated for three days in order to measure growth inhibition. A Coulter Counter is used to calculate cell numbers. Trypan blue (0.4% volume) is added to an aliquot of cells to dilute it. The percentage of cells that have not included trypan blue is used to determine viability. Colonies are counted after two weeks of growth for cells cultured with Cisplatin as previously described, after which they are diluted into 0.1% agar.
|
|
| Animal Protocol |
Mice: There are twenty mice per group, which are randomly assigned to three groups: Control, Cisplatin, and Cisplatin+HemoHIM. A subcutaneous femoral left region in mice is injected with B16F0 melanoma (5×105 cells/mouse) three days prior to the first Cisplatin injection. Three injections of 4 mg/kg body weight (B.W.) of cisplatin are administered intraperitoneally on days 0 through 14. Day 0 to Day 16 see daily intubations of the experimental group with HemoHIM at a final concentration of 100 mg/kgB.W., while the control group was given only water. Each group's mice undergo experiments on day 17 following their first Cisplatin injection in order to assess the tumors' size or weight. The tumor size is calculated as follows: tumor size=ab2/2, where a and b are the larger and smaller diameters, respectively.
Rats: Four groups of four or five male Sprague-Dawley rats, weighing 200 to 250 g apiece, are randomly assigned. First, a vehicle containing 5% carboxymethyl cellulose sodium solution (CMC-Na), 5 mL/kg body weight, p.o., was administered to the control group (Cap). The third group was injected with 5% CMC-Na for six consecutive days along with 5 mg/kg of Cisplatin in physiological saline solution intraperitoneally (i.p.). The second group received Cap (10 mg/kg/d, p.o.) in 5% CMC-Na (5 mL/kg). Six days straight after receiving an injection of 5 mg/kg of Cisplatin intraperitoneally (i.p.), the fourth group was given Cap (10 mg/kg/d, p.o.) in 5% CMC-Na. Every group receives a cap or vehicle twice a day. Data from our preliminary experiments are used to determine the chosen Cap concentration and the dose administration schedule without causing any intestinal damage in rats. |
|
| References |
| Molecular Formula |
CL2H6N2PT
|
|
|---|---|---|
| Molecular Weight |
300.05
|
|
| Elemental Analysis |
Cl, 23.63; H, 2.02; N, 9.34; Pt, 65.02
|
|
| CAS # |
15663-27-1
|
|
| Related CAS # |
|
|
| Appearance |
Yellow solid powder
|
|
| SMILES |
Cl[Pt-2]([NH3+])([NH3+])Cl
|
|
| InChi Key |
LXZZYRPGZAFOLE-UHFFFAOYSA-L
|
|
| InChi Code |
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
|
|
| Chemical Name |
(SP-4-2)-diamminedichloroplatinum; platinum, diaminedichloro-, cis-
|
|
| Synonyms |
Cismaplat; Cisplatina; cisplatinous diamine dichloride; cisplatinum; cisplatinum II; cisplatinum II diamine dichloride; CDDP; DDP; cisDDP; cisdiamminedichloro platinum (II); cisdiamminedichloroplatinum; Cisdichloroammine Platinum (II); CPDD; Cysplatyna; DDP; PDD; Peyrones Chloride; Peyrones Salt; CACP; Platinoxan; platinum diamminodichloride. Trade names (US): Platinol; PlatinolAQ. Trade names (other countries): Abiplatin; Blastolem; Briplatin; Cisplatyl; Citoplatino; Citosin; Lederplatin; Metaplatin; Neoplatin; Placis; Platamine; Platiblastin; PlatiblastinS; Platinex; Platinol AQ; PlatinolAQ VHA Plus; Platiran; Platistin; Platosin.
|
|
| HS Tariff Code |
2843.90.0000
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (33.33 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 20 mg/mL (66.66 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View MoreSolubility in Formulation 3: Saline: 3 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3328 mL | 16.6639 mL | 33.3278 mL | |
| 5 mM | 0.6666 mL | 3.3328 mL | 6.6656 mL | |
| 10 mM | 0.3333 mL | 1.6664 mL | 3.3328 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03558087 | Active Recruiting |
Drug: Nivolumab Drug: Cisplatin |
Bladder Cancer | Matthew Galsky | July 13, 2018 | Phase 2 |
| NCT01670500 | Active Recruiting |
Drug: Cisplatin Drug: Doxorubicin |
Breast Cancer | Beth Israel Deaconess Medical Center |
October 2012 | Phase 2 |
| NCT03809637 | Active Recruiting |
Drug: Pemetrexed, cisplatin | Yonsei University | Sarcoma | January 10, 2017 | Phase 2 |
| NCT03345784 | Active Recruiting |
Drug: Cisplatin Drug: Adavosertib |
Cervical Carcinoma Vaginal Carcinoma |
National Cancer Institute (NCI) |
May 29, 2018 | Phase 1 |
| NCT04003636 | Active Recruiting |
Drug: Cisplatin Drug: Placebo |
Biliary Tract Carcinoma | Merck Sharp & Dohme LLC | September 24, 2019 | Phase 3 |
The inhibition of tumor growth was enhanced by HemoHIM administration in melanoma-bearing mice which were injected with cisplatin.BMC Cancer.2009 Mar 17;9:85. |
|---|
Growth inhibition effect of cisplatin and HemoHIM on melanoma cellsin vitro.BMC Cancer.2009 Mar 17;9:85. |
HemoHIM administration promotes immune responses for tumor surveillance in melanoma-bearing mice which were injected with cisplatin.BMC Cancer.2009 Mar 17;9:85. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
